CD8A and acute lymphoblastic leukemia: Additionally, IFNγ ELISpot assays demonstrated that two cancer-specific ereMAPs (i.e., not expressed by mTECs), identified by Laumont et al. [27] on B-ALL samples, have the ability to activate CD8 T cells (Additional file 2: Fig. S7B, C).